No profile data available.
Niagen Bioscience, Inc. (NAGE) is a healthcare company in the nutritional and natural health products industry, based in Los Angeles, United States, with about 117 full-time employees.
It reported revenue of $99.60 million for fiscal year 2024, up 19.2% from fiscal year 2023, and net income of $8.55 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $33.99 million, up 32.9% from a year before. Its largest business segment, Consumer Products, brought in 75% of segment revenue in fiscal year 2025; United States was the largest region with 79%. Its market capitalization was $214.24 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments.
Niagen Bioscience reported $99.60 million in revenue for fiscal year 2024, up 19.2% from $83.57 million in fiscal year 2023. In Q3 2025 revenue was $33.99 million.
Consumer Products, with $97.67 million or 75% of segment revenue in fiscal year 2025. Next: Ingredients (22%) and Analytical Reference Standards and Services (2%).
United States: 79% of revenue by region in fiscal year 2025, followed by International (21%).
$214.24 million as of October 9, 2026.
Listed companies of a similar size in the same industry (nutritional and natural health products) include Regencell Bioscience Holdings Limited (RGC), Usana Health Sciences, Inc. (USNA), Nature's Sunshine Products, Inc. (NATR), LifeVantage Corporation (LFVN).